Escherichia coli

DB16539InvestigationalOrganism Based Therapies

Escherichia coli is a probiotic indicated to treat urinary tract infections and irritable bowel syndrome.

Mechanism
Curator reviewed
Also known as
E. Coli

Resolves to

Compound
UNII514B9K0L10CAS68583-22-2
Clinical / RWD
RxNorm350202ATCA07FA03
Targets
O00206TLR4

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
87Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
8ContraindicationsEach with its own population and attribute set
Sign in
2Marketed productsAcross 1 country and 2 labellers
Sign in
1ATC codeIncluding every combination product, plus 3 drug categories
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Escherichia coli, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In